NCT00919893 is a Phase 3 clinical trial of Cernilton in Chronic Prostatitis, sponsored by University of Giessen.

Who is sponsoring NCT00919893?

NCT00919893 is sponsored by University of Giessen.

What drugs are being tested in NCT00919893?

Interventions in NCT00919893: Cernilton, Placebo.

What condition does NCT00919893 study?

NCT00919893 studies Chronic Prostatitis, Chronic Pelvic Pain Syndrome.

Is NCT00919893 still recruiting?

NCT00919893 is currently completed. Last updated 4 November 2020.

Are results published for NCT00919893?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-11-04 · How we verify

NCT00919893

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-chronic Pelvic Pain Syndrome

Completed Phase 3 Results posted Last updated 4 November 2020

What this trial tests

Phase 3 trial testing Cernilton in Chronic Prostatitis in 139 participants. Completed in 1 January 2004.

Timeline

1 December 1999

Primary endpoint
1 January 2004

1 January 2004

Quick facts

Lead sponsor	University of Giessen
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	139
Start date	1 December 1999
Primary completion	1 January 2004
Estimated completion	1 January 2004
Sites	1 location across Germany

Drugs / interventions tested

Cernilton — full drug profile →
Placebo

Conditions studied

Chronic Prostatitis — all drugs for Chronic Prostatitis →
Chronic Pelvic Pain Syndrome — all drugs for Chronic Pelvic Pain Syndrome →

Sponsor

University of Giessen

Who can join

Adults 18 to 65, male only, with Chronic Prostatitis or Chronic Pelvic Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI)
Time frame: 0, 6, 12 weeks
Decrease in NIH-CPSI pain score. Best value: 0. Worst value: 21.

Sponsor's own description

In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Prostatitis

Currently open trials in the same condition.

NCT06299683 — Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment · NA · recruiting
NCT06287970 — TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS · NA · recruiting
NCT06345014 — The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome · Phase 4 · recruiting

Other University of Giessen trials

Trials by the same sponsor.

NCT07505511 — Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in · EARLY_PHASE1 · not yet recruiting
NCT07488468 — Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures · recruiting
NCT06966739 — Multispectral Optoacustic Imaging in Patients With Myositis · completed
NCT06381427 — Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure · NA · recruiting
NCT06291714 — Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00919893 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Giessen
Last refreshed: 4 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00919893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing